# EDGAR Filing Document

**Accession Number:** 0001859007
**File Stem:** 0001493152-23-004551
**Filing Date:** 2023-2
**Character Count:** 2809
**Document Hash:** bfd63e209d99c89e7b988a3deebcbd85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-004551.hdr.sgml**: 20230524

**ACCESSION NUMBER**: 0001493152-23-004551

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZyVersa Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001859007
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 862685744
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876
- **BUSINESS PHONE:** 908-370-5102

**MAIL ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Larkspur Health Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210426

**A.G.P./ALLIANCE GLOBAL PARTNERS**

590 Madison Avenue 28th Floor New York,

New York 10022

February 13, 2023

**<u>VIA EDGAR</u>**

Securities and Exchange Commission 100 F Street, N.E.

Division of Corporation Finance

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **ZyVersa Therapeutics, Inc. (the "Company")** |
|  | **Registration Statement on Form S-1** |
|  | **File No. 333- 269442 (the "Registration Statement")** |

---

Ladies and Gentlemen:

In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, (the "Act"), A.G.P./Alliance Global Partners, as the lead placement agent, hereby joins the Company's request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:30 p.m., Eastern Time on February 14, 2023, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we wish to advise you that the placement agents have distributed as many copies of the Preliminary Prospectus to dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.

The undersigned, as the lead placement agent, represents that the co-placement agent has and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Please contact Katherine J. Blair of Manatt, Phelps & Phillips, LLP, counsel of the lead placement agent, at (310) 312-4252 to provide notice of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.

[*Signature page follows*]

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **A.G.P./ALLIANCE GLOBAL PARTNERS** | **A.G.P./ALLIANCE GLOBAL PARTNERS** |
| By: | */s/ Thomas Higgins* |
| Name: | Thomas Higgins |
| Title: | Managing Director |

---